Eun Yang
Stock Analyst at Jefferies
(0.36)
# 4,153
Out of 4,944 analysts
34
Total ratings
26.32%
Success rate
-28.63%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $309.72 | +39.48% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $3.03 | +164.03% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $6.87 | +293.01% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.54 | +180.16% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $50.38 | -34.50% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.72 | +1,527.91% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $19.99 | +35.10% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.62 | +332.10% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.50 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $3.81 | +556.17% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $4.55 | +329,570.33% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.07 | +2,236.45% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.14 | +104.20% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $289.33 | -23.96% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $135.19 | +129.31% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $120.14 | -33.41% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $309.72
Upside: +39.48%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $3.03
Upside: +164.03%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $6.87
Upside: +293.01%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.54
Upside: +180.16%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $50.38
Upside: -34.50%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.72
Upside: +1,527.91%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $19.99
Upside: +35.10%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.62
Upside: +332.10%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.50
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.81
Upside: +556.17%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $4.55
Upside: +329,570.33%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.07
Upside: +2,236.45%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $17.14
Upside: +104.20%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $289.33
Upside: -23.96%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $135.19
Upside: +129.31%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $120.14
Upside: -33.41%